Affirmed Therapeutics BV Company Profile (NASDAQ:AFMD)

About Affirmed Therapeutics BV

Affirmed Therapeutics BV logoAffimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company's product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its pipeline includes FM13, AFM11, AFM21, AFM22, AFM24, TandAb and Trispecific Abs. It has started recruitment for Phase IIa clinical trial of AFM13 in patients with Hodgkin Lymphoma. It has initiated a Phase I clinical trial of AFM11 in patients with non-Hodgkin Lymphoma. AFM21 is in preclinical development. AFM22, which is an Epidermal Growth Factor Receptor variant III (EGFRvIII)/CD16A NK-cell TandAb is in preclinical development. AFM24 is an additional CD16A NK-cell TandAb targeting a validated solid tumor target, EGFR-wild type. It is developing Trispecific Abs for treating multiple myeloma, and CD33/CD3-specific T-cell TandAb to treat acute myeloid leukemia.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: AFMD
  • CUSIP:
Key Metrics:
  • Previous Close: $2.30
  • 50 Day Moving Average: $2.67
  • 200 Day Moving Average: $3.13
  • 52-Week Range: $2.10 - $8.26
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.10
  • P/E Growth: 0.00
  • Market Cap: $73.67M
  • Outstanding Shares: 33,487,000
  • Beta: 3.7
  • Net Margins: -440.97%
  • Return on Equity: -49.84%
  • Return on Assets: -42.35%
  • Debt-to-Equity Ratio: 0.04%
  • Current Ratio: 8.73%
  • Quick Ratio: 8.70%
Additional Links:
Companies Related to Affirmed Therapeutics BV:

Analyst Ratings

Consensus Ratings for Affirmed Therapeutics BV (NASDAQ:AFMD) (?)
Ratings Breakdown: 2 Hold Ratings, 4 Buy Ratings
Consensus Rating:Buy (Score: 2.67)
Consensus Price Target: $9.60 (326.67% upside)

Analysts' Ratings History for Affirmed Therapeutics BV (NASDAQ:AFMD)
DateFirmActionRatingPrice TargetDetails
8/12/2016Leerink SwannDowngradeOutperform -> Market Perform$8.00 -> $3.00View Rating Details
8/9/2016Jefferies GroupReiterated RatingHoldView Rating Details
5/18/2016Wells Fargo & Co.Reiterated RatingBuyView Rating Details
4/11/2016BMO Capital MarketsInitiated CoverageOutperform$7.00View Rating Details
12/10/2015LaidlawInitiated CoverageBuy$15.00View Rating Details
11/20/2015Oppenheimer Holdings Inc.Reiterated RatingOutperform$19.00View Rating Details
(Data available from 10/25/2014 forward)


Earnings History for Affirmed Therapeutics BV (NASDAQ:AFMD)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/10/2016Q216($0.22)($0.27)$2.10 million$2.07 millionViewListenView Earnings Details
5/18/2016Q116($0.17)($0.25)$1.88 million$1.90 millionViewListenView Earnings Details
3/30/2016Q415($0.18)($0.22)$1.71 million$1.66 millionViewListenView Earnings Details
11/10/2015Q315($0.25)($0.24)$1.87 million$1.20 millionViewListenView Earnings Details
8/4/2015Q215($0.14)($0.21)$2.56 million$2.21 millionViewN/AView Earnings Details
5/21/2015Q115($0.14)($0.07)ViewListenView Earnings Details
3/25/2015Q414($0.33)($0.22)ViewN/AView Earnings Details
11/18/2014Q314($0.33)$2.69ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Affirmed Therapeutics BV (NASDAQ:AFMD)
Current Year EPS Consensus Estimate: $-1.08 EPS
Next Year EPS Consensus Estimate: $-1.07 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.28)($0.28)($0.28)
Q2 20162($0.29)($0.14)($0.22)
Q3 20162($0.29)($0.23)($0.26)
Q4 20163($0.30)($0.19)($0.24)
(Data provided by Zacks Investment Research)


Dividend History for Affirmed Therapeutics BV (NASDAQ:AFMD)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Affirmed Therapeutics BV (NASDAQ:AFMD)
No insider trades for this company have been tracked by


Latest Headlines for Affirmed Therapeutics BV (NASDAQ:AFMD)
News IconPenny Stock Investors are Growing Curious About Affimed N.V. (NASDAQ:AFMD) - Duncan Research (NASDAQ:AFMD) - September 30 at 8:14 AM logoAffimed to Present at the Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology (NASDAQ:AFMD) - September 22 at 8:58 AM logoAffimed to Present at Upcoming Investor Conferences (NASDAQ:AFMD) - September 1 at 11:49 AM
News IconAffirmed Therapeutics BV (NASDAQ: AFMD) announces quarterly earnings - BNB Daily (blog) (NASDAQ:AFMD) - August 11 at 3:23 PM logoAffirmed Therapeutics reports 2Q loss (NASDAQ:AFMD) - August 10 at 12:41 PM logoAffimed Reports Financial Results for Second Quarter 2016 and Provides Corporate Update (NASDAQ:AFMD) - August 10 at 12:41 PM logoAffimed Announces Second Quarter 2016 Financial Results and Corporate Update Conference Call (NASDAQ:AFMD) - August 3 at 11:55 AM
News IconAffimed N.V. (NASDAQ:AFMD) Earnings Glance and Target Price Review - Engelwood Daily (NASDAQ:AFMD) - June 30 at 3:23 PM
News IconAffimed NV (NASDAQ: AFMD) Set To Develop Clinical Candidate is AFM13 - Scibility Media (NASDAQ:AFMD) - June 29 at 3:19 PM logoStrong Sell Calls Recommendations For Affimed N.V. (NASDAQ:AFMD) At 0 - Investor Newswire (NASDAQ:AFMD) - June 27 at 8:07 AM
News IconAffimed NV (NASDAQ:AFMD) Earnings Glance and Target Price Review - Engelwood Daily (NASDAQ:AFMD) - June 23 at 10:47 PM logoAffimed NV (NasdaqGM:AFMD) Stock Momentum Hits EXTREME Weakness - CML News (NASDAQ:AFMD) - June 22 at 3:20 PM logoStrong Buy Calls Count For Affimed N.V. (NASDAQ:AFMD) At 3 - Investor Newswire (NASDAQ:AFMD) - June 20 at 9:52 AM logoTrend Of Rating Given To Affimed N.V. (NASDAQ:AFMD) - Investor Newswire (NASDAQ:AFMD) - June 12 at 8:40 PM logoAffimed N.V. (NASDAQ:AFMD) Dropped-9.07%: Verizon Communications Inc. (NYSE:VZ), Del Frisco's Restaurant ... - KC Register (NASDAQ:AFMD) - June 10 at 3:23 PM
News IconStock Review and Earnings Check on Affimed N.V. (NASDAQ:AFMD) - HNN (NASDAQ:AFMD) - June 3 at 11:50 AM logoThese 7 Stocks Under $10 Are About to Break Out (NASDAQ:AFMD) - June 3 at 7:55 AM
News IconTarget Price and Stock Performance Rundown for Affimed N.V. (NASDAQ:AFMD) - HNN (NASDAQ:AFMD) - June 1 at 3:23 PM
News IconAffimed N.V. (NASDAQ:AFMD) Stock Update & Estimates - Stock Tick Tock (NASDAQ:AFMD) - June 1 at 11:42 AM logoAffimed to Present at the Jefferies 2016 Healthcare Conference (NASDAQ:AFMD) - May 31 at 5:22 AM
News IconAffimed NV (NASDAQ:AFMD) Given Average Rating of “Buy” by Analysts - Let Me Know About This (NASDAQ:AFMD) - May 30 at 9:52 PM
News IconEarnings Review and Stock Rundown for Affimed N.V. (NASDAQ:AFMD) - Wall Street Hints and News (NASDAQ:AFMD) - May 28 at 2:46 PM logoLeerink Swann Downgrades Affimed NV to Market Perform - Trade Calls (NASDAQ:AFMD) - May 26 at 2:50 PM logoAffimed Announces Annual General Meeting of Shareholders (NASDAQ:AFMD) - May 24 at 4:16 AM logoAffimed Therapeutics downgraded by Leerink Partners (NASDAQ:AFMD) - May 19 at 9:17 AM logoAffimed Reports Financial Results for First Quarter 2016 (NASDAQ:AFMD) - May 18 at 7:52 AM logoQ1 2016 Affimed NV Earnings Release - Time Not Supplied (NASDAQ:AFMD) - May 18 at 7:07 AM logoAffimed to Present at the UBS Global Healthcare Conference -- New York (NASDAQ:AFMD) - May 17 at 5:00 AM logoAffimed Announces First Quarter 2016 Financial Results and Corporate Update Conference Call (NASDAQ:AFMD) - May 11 at 5:22 AM logoETF’s with exposure to Affimed NV : May 5, 2016 (NASDAQ:AFMD) - May 5 at 4:48 PM logoAffimed Presents Data on EGFRwt and EGFRvIII-targeting NK- and T-Cell TandAbs at the AACR Annual Meeting 2016 (NASDAQ:AFMD) - April 21 at 5:17 AM logoAffimed Presents Data on AFM13-mediated Innate/Adaptive Immune Crosstalk at the AACR Annual Meeting 2016 (NASDAQ:AFMD) - April 21 at 5:17 AM
News IconAffimed NV (AFMD): Samuel Isaly Unloads Shares of Sinking Stock (NASDAQ:AFMD) - March 31 at 8:32 PM
News IconAre Analysts Bearish Affimed NV (NASDAQ:AFMD) After Last Week? - (NASDAQ:AFMD) - February 26 at 12:52 PM logoAffimed to Speak at Symposium on Emerging Approaches in Cancer Immunotherapy (NASDAQ:AFMD) - February 22 at 5:00 AM
News IconAffimed NV (NASDAQ:AFMD) Shorted Shares Increased 28.98% After Market Selling - (NASDAQ:AFMD) - February 14 at 2:25 PM
News IconAffimed NV (NASDAQ:AFMD) Shorted Shares Increased By 26.79% - (NASDAQ:AFMD) - February 5 at 2:35 PM logoAffimed N.V. (NASDAQ:AFMD): Quarterly Earnings Update - Investor Newswire (NASDAQ:AFMD) - February 4 at 2:30 PM logoAffimed to Present at the Leerink Partners 5th Annual Global Healthcare Conference (NASDAQ:AFMD) - February 4 at 5:00 AM logoAffimed N.V. (NASDAQ:AFMD) Analyst Rating Update - Investor Newswire (NASDAQ:AFMD) - January 30 at 1:38 PM
News IconAffimed N.V. (NASDAQ:AFMD) Short Interest Update - WallStreet Prudent (NASDAQ:AFMD) - January 28 at 1:51 PM
News IconCompany Shares of Affimed NV (NASDAQ:AFMD) Rally 1.65% - WallStreet Prudent (NASDAQ:AFMD) - January 24 at 7:36 PM logoAffimed Appoints Dr. Joerg Windisch as Chief Operating Officer and Adds Dr. Bernhard Ehmer to Supervisory Board (NASDAQ:AFMD) - January 21 at 10:06 AM logo10:00 am Affimed Therapeutics names Dr. Joerg Windisch as COO (NASDAQ:AFMD) - January 21 at 10:00 AM logoAffimed to Host Hodgkin’s Lymphoma Day with Key Opinion Leaders on January 26th in New York (NASDAQ:AFMD) - January 20 at 5:25 AM logoAffimed to Host Hodgkin's Lymphoma Day with Key Opinion Leaders on January 26th in New York City (NASDAQ:AFMD) - January 20 at 5:00 AM logoAffimed N.V. (NASDAQ:AFMD) - Stock Sentiment And ABR Update - Investor Newswire (NASDAQ:AFMD) - January 18 at 7:39 PM logoAnalysts Review: Affimed NV - iStreetWire (NASDAQ:AFMD) - January 18 at 12:12 PM logoWhy Biotech Affimed N.V. Should Be On Your Radar (NASDAQ:AFMD) - December 8 at 8:00 AM logoAffimed Presents Data Comparing T-cell- and NK-cell-engaging TandAbs AFM11 and AFM12 at ASH (NASDAQ:AFMD) - December 6 at 9:29 AM


Affirmed Therapeutics BV (NASDAQ:AFMD) Chart for Tuesday, October, 25, 2016

Last Updated on 10/25/2016 by Staff